Aetna considers stereotactic radiosurgery medically necessary according to the following selection criteria.

1. Cranial stereotactic radiosurgery with a gamma knife, Cyberknife, or linear accelerator (LINAC) is considered medically necessary when used for any of the following indications:

   1. For treatment of members with symptomatic, small (less than 3 cm) arterio-venous (AV) malformations, aneurysms, and benign tumors (acoustic neuromas (vestibular schwannomas), meningiomas, hemangiomas, pituitary adenomas, craniopharyngiomas, and neoplasms of the pineal gland) if the lesion is unresectable due to its deep intracranial location or if the member is unable to tolerate conventional operative intervention; or
   2. For members with trigeminal neuralgia that has not responded to other more conservative treatments (see CPB 374 - Trigeminal Neuralgia Surgery); or

   3. For treatment of brain malignancies.

2. Stereotactic body radiation  therapy (SBRT) with a gamma knife, Cyberknife, or linear accelerator (LINAC) is considered medically necessary for localized malignant conditions within the body where highly precise application of high-dose radiotherapy is required.

3. Fractionated stereotactic radiotherapy is considered medically necessary when criteria for stereotactic radiosurgery are met. Fractionated stereotactic radiotherapy is useful for treatment of tumors in hard-to-reach locations, tumors with very unusual shapes, or for tumors located in such close proximity to a vital structure (e.g., optic nerve or hypothalamus) that even a very accurate high-dose single fraction of stereotactic radiosurgery could not be tolerated.

4. Stereotactic proton beam radiosurgery: please see CPB 270 - Proton Beam and Neutron Bean Radiotherapy.

Aetna considers stereotactic radiosurgery experimental and investigational for all other indications including:

1. Parkinson's disease
2. Epilepsy (except when associated with treatment of AV malformations or brain tumors)
3. Cluster headaches.

With any external beam radiation therapy, the highest dose of radiation develops where multiple beams intersect.  Thus, the fewer beams there are, the greater the dose reaching other areas traversed by the beams.  For example, if only two beams are used, the highest dose would develop at the site where the beams intersect, but a significant portion of the dose would be distributed to fields anterior and posterior to the intersection.

Stereotactic radiosurgery (SRS) uses the above principle to deliver a highly focused ionizing beam so that the desired target is obliterated, leaving adjacent structures nearly unaffected. Guidance is provided by a variety of imaging techniques, including angiography, computerized tomography (CT), and magnetic resonance imaging (MRI).  The key to SRS is immobilization of the patient so that targeting can be accurate and precise. 

Stereotactic radiation is also used in extracranial sites, in a procedure called stereotactic body radiation therapy (SBRT).  A body frame has been designed to immobilize patients for such treatment.  In addition, frameless methods of administering SBRT to the body have been developed.  These frameless systems rely on skeletal landmarks or implanted fiducial markers to locate and guide the therapy beam to treatment targets within the body.

Based upon professional opinion, a coding guide from the American Society for Therapeutic Radiation and Oncology (ASTRO, 2007) stated that SBRT is considered appropriate for the treatment of the following conditions:

• Medically inoperable early stage lung cancer
• Recurrent lung cancer amenable to salvage therapy
• Primary liver cancer not amenable to surgery
• Lung or liver metastases not amenable to surgery
• Retroperitoneal tumors
• Recurrent pelvic tumors
• Spinal and parapsinous tumors
• Other recurrent cancers or tumors.

The radioactive particles used in SRS and SBRT may come from various sources.  The Gamma Knife uses Cobalt-60.  Over 200 finely focused beams of gamma radiation simultaneously intersect at the precise location of the brain disorder.  Proton beam radiosurgery derives its advantage from the so-called "Bragg peak", a term that describes the pattern of deposition of proton beam radiation. Protons decelerate as they travel though tissue, depositing disproportionately more radiation at greater depths.  The protons deposit most of their energy at their depth of maximal penetration, resulting in a "peak" of radiation at that tissue depth.  The depth of peak radiation can be precisely defined by the energy the cyclotron imparts to the proton beam.

A linear accelerator, or LINAC, creates photons by accelerating electrons along a linear path where they collide with a metal target.  This produces a single, intense photon beam.  To reduce the effect of the radiation on adjacent healthy tissues, a moving frame is used to target the abnormality with "arcs" from different directions. LINAC treatments may be given in multiple sessions over several days, which are referred to as fractionated radiotherapy.  With fractionated radiotherapy, radiation is delivered to the tumor or lesion at different points in the cell division cycle.  This may be the preferred form of treatment in some circumstances.  Fractionated treatments may continue for up to 30 days. "Hypofractionated" treatments are given over five to eight treatment days.

Precise stereotactic localization is necessary for treatment of intracranial structures, because of their deep location and because of the close proximity of vital structures in the brain.  During radiotherapy administration, the cranium can be completely immobilized using a frame. 

Fractionated stereotactic radiotherapy (FSRT) involves multiple low-dose radiation treatments.  Fractionated stereotactic radiotherapy is used to treat tumors in hard-to-reach locations or with very unusual shapes.  Fractionated stereotactic radiotherapy is also used to treat tumors which are located in close proximity to vital structures, such as the optic nerve or hypothalamus, where even a very accurate high-dose single fraction of stereotactic radiosurgery could not be tolerated.

For this procedure, patients are required to wear a special customized fiberglass helmet.  (For other stereotactic radiation techniques of the head, the patient's head must be immobilized in a special head-ring frame, which is applied under local anesthetic.)  After the patient undergoes the usual stereotactic imaging such as CT or MR, small doses of radiation are accurately applied each day.  The customized fiberglass helmet harnesses the patient while receiving low, daily doses.  Fractionated stereotactic radiotherapy is also an excellent way to administer radiation treatments to infants or small children whose fast-growing brains cannot tolerate standard radiation. In the past, oncologists were limited to treating infants and small children with chemotherapy alone.  This technique also shows great promise in the treatment of benign tumors such as pituitary adenomas or meningiomas.  The use of fractionated stereotactic radiotherapy permits excellent control of the tumor but spares the brain from such cognitive side-effects as impaired cognition and memory that commonly occur with standard radiation treatment.

An assessment conducted by the Alberta Heritage Foundation for Medical Research (Hailey, 2002) concluded that there is limited evidence that fractionated stereotactic radiotherapy may have an advantage over stereotactic radiosurgery in treatment of acoustic neuromas and brain tumors.

There are clinical reports of the effectiveness of of SBRT for radiosensitive CNS tumors invading the spine. SBRT is useful to treat surgically unresectable ependymomas and other radiosensitive primary central nervous system tumors if they are invading the spine and spinal cord. SBRT has not been as successful when used on metastatic tumors to the spine, because these metastatic lesions are not usually radiosensitive. SBRT of the spine has been performed using an immobilizing frame. In addition, frameless methods of administering SBRT to the spine are in development.  These frameless systems rely on skeletal landmarks or implanted fiducial markers to locate and guide the therapy beam to treatment targets within the spine or spinal cord.

With the development of a stereotactic body frame analogous to the stereotactic head frames used for intracranial targets, stereotactic techniques have been used to treat tumors in extracranial sites other than the spine.  Available evidence for SBRT is from dose analysis studies showing theoretical advantage to this form of treatment, and Phase II studies evaluating local control and toxicity. 

A number of studies have examined SBRT of primary lung cancer.  Nyman, et al. (2005) from Finland reported experience of SBRT in 45 patients with Stage I non-small cell lung cancer.  The investigators reported 80 percent 1 year survival and 30 percent 5 year survival, and median survival of 39 months.  Nagata, et al. (2005) reported on experience from Japan on SBRT in 45 patients with Stage IA and IB lung cancer.  Sixteen percent of tumors showed complete response, and 84 percent of tumors showed partial response.  With a median follow-up of 30 months, no pulmonary complications greater than grade 3 were found and no other vascular, cardiac, esophageal or neurologic toxicities encountered.  The investigators reported that, for Stage IA lung cancer, the disease-free and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively.  McGarry, et al. (2003) from Indiana University reported on a Phase I dose escalation study of  SBRT in 47 patients with inoperable Stage I lung cancer.  Dose-limiting toxicity included predominantly bronchitis, pericardial effusion, hypoxia, and pneumonitis.  Local failure occurred in 4 of 19 T1 and 6 of 28 T2 patients.  Local failures occurred between 3 and 31 months from treatment.  Within the T1 group, five patients had distant or regional recurrence as an isolated group, whereas three patients had both distant and regional recurrence.  Within the T2 group, two patients had solitary regional recurrences, and the four patients who failed distantly also failed regionally.

An earlier report from Indiana University details Phase I trial experience with 37 patients with Stage I non-small cell lung cancer treated with SBRT (Timmerman, et al., 2003).  Significant toxicity was limited to one case of Grade 3 pneumonitis and one case of hypoxia.  Minor transient pulmonary function changes were commonly seen, and one case of asymptomatic pericardial effusion was noted.  Twenty-seven patients had a complete response to treatment, and 60 percent of patients had a partial response.  After a median follow-up period of 15.2 months, six patients experienced local failure, all at lower dose levels than currently employed.   A 2003 Korean study reported experience using SBRT in 28 patients with primary or metastatic lung tumors (Lee. et al., 2003).  A hypofractionated three or four treatment regimen was used.  Thirty-nine percent complete and 43% partial response rates were noted.  Whyte, et al. (2003) from Stanford University reported on a Phase I clinical trial of SBRT in 23 patients with lung cancer.  Complete radiographic responses were seen in two patients, partial responses in 15 patients, and no response or progression in 6 patients.  Three pneumothoraces resulted from fiducial placement.  A 2001 Japanese report detailed a 5-year experience in treating 50 patients with Stage I non-small cell lung cancer.  In 18 of these patients, SBRT was boost treatment after conventional radiotherapy.  With a median 36-month follow-up, 30 patients were alive and disease-free.  The 3-year case-specific survival rate was 88 percent.   The Radiation Therapy Oncology Group has an ongoing clinical study of SBRT in patients with inoperable Stage I/II non-small cell lung cancer.

There are studies of SBRT in body sites other than the spine and lung.  Schefter, et al. (2001) reported on a Phase I clinical trial of stereotactic body radiotherapy in 18 patients with metastatic liver cancer.  The study was limited to patients with one to three liver metastases, tumor diameter less than 6 cm, and adequate liver function. The investigators reported that no patients experienced acute Grade 3 liver or intestinal toxicity or any acute Grade 4 toxicity. 

Hoyer, et al. (2005) from Denmark reported on a Phase II study of SBRT in pancreatic cancer.  Twenty-two patients with locally advanced and surgically non-resectable, histological proven pancreatic carcinoma were included into the trial.  The investigators reported that only two patients were found to have a partial response, and the remaining patients had no change or progression after treatment.  Six patients had local tumor progression, but only one patient had an isolated local failure without simultaneous distant metastasis.  The investigators reported that median time to local or distant progression was 4.8 months.  Median survival time was 5.7 months and only 5% of patients were alive 1 year after treatment.  The investigators noted that acute toxicity reported 14 days after treatment was pronounced.  The investigators stated that there was a significant deterioration of performance status, significantly more nausea and significantly more pain after 14 days compared with baseline. However, 8 of 12 patients improved in performance status, scored less nausea, pain, or needed less analgesic drugs at 3 months after treatment.  Four patients suffered from severe mucositis or ulceration of the stomach or duodenum and one of the patients had a non-fatal ulcer perforation of the stomach.  The investigators concluded that SBRT “was associated with poor outcome, unacceptable toxicity and questionable palliative effect and cannot be recommended for patients with advanced pancreatic carcinoma.”

Wersall, et al. (2005) from Sweden investigated the results of using SBRT in 58 patients with renal cell carcinomas.  The investigators reported that tumor lesions regressed totally in 30% of the patients at three to 36 months, whereas 60% of the patients had a partial volume reduction or no change after a median follow-up of 37 months for censored and 13 months for uncensored patients. The investigators reported that side effects were generally mild.  The investigators reported that three of 162 treated tumors recurred, yielding a local control rate of 90-98%, considering the 8% non-evaluable sites.

Hoyer, et al. (2006) evaluated the effectiveness of SBRT in the treatment of inoperable patients with colorectal cancer metastases. Sixty-four patients with a total number of 141 colorectal cancer metastases in the liver (n = 44), lung (n = 12), lymph nodes (n = 3), suprarenal gland (n = 1) or two organs (n = 4) were treated with SBRT. After 2 years, actuarial local control was 86% and 63% in tumor and patient based analysis, respectively. Nineteen percent were without local or distant progression after 2 years and overall survival was 67, 38, 22, 13, and 13% after 1, 2, 3, 4 and 5 years, respectively. The investigators reported that one patient died due to hepatic failure, one patient was operated for a colonic perforation and two patients were conservatively treated for duodenal ulcerations. In addition, moderate toxicities such as nausea, diarrhoea and skin reactions were observed.

A structured evidence review by the Alberta Heritage Foundation for Medical Research (Hailey, 2002) concluded that "the place of SRS [stereotactic radiosurgery] in the treatment of Parkinson's disease does not appear to be established."  In addition, the review concluded that "[t]he efficacy of SRS in the management of epilepsy appears not to have been established, other than in association with its use in treatment for AVMs or brain tumors."

Bartolomei et al (2008) reported the effectiveness and tolerance of gamma knife (GK) radiosurgery in mesial temporal lobe epilepsy (MTLE) after a follow-up more than 5 years. Patients presenting with MTLE and treated with a marginal dose of 24 Gy were included in the study (n = 15) -- 8 were treated on the left side, and 7 were treated on the right. The mean follow-up was 8 years (range of 6 to 10 years). At the last follow-up, 9 of 16 patients (60 %) were considered seizure-free (Engel Class I) (4/16 in Class IA, 5/16 in Class IB). Seizure cessation occurred with a mean delay of 12 months (+/- 3) after GK radiosurgery, often preceded by a period of increasing aura or seizure occurrence (6/15 patients). The mean delay of appearance of the first neuroradiological changes was 12 months (+/- 4). Nine patients (60 %) experienced mild headache and were placed on corticosteroid treatment for a short period. All patients who were initially seizure-free experienced a relapse of isolated aura (10/15, 66 %) or complex partial seizures (10/15, 66 %) during anti-epileptic drug (AED) tapering. Restoration of treatment resulted in good control of seizures. The authors concluded that GK radiosurgery is an effective and safe treatment for MTLE. Results are maintained over time with no additional side effects. Long-term results compare well with those of conventional surgery. The authors also noted that the main disadvantage of this approach is the delay of seizure remission, often preceded by a period of increasing seizure frequency. Patients must also be warned that a long-lasting AED treatment must be maintained (usually at a lower dose) following the procedure.

In an editorial that accompanied the afore-mention article, Spencer (2008) stated that GK treatment in MTLE is still searching for a place; its disadvantages (slightly lower seizure response rate, delayed response, absolute requirement for continued medication, higher mortality) compared to anterior medial temporal resection seem to outweigh its non-invasive status, which so far does not appear to carry any clear benefits in terms of neurological or cognitive function, or seizure response. Furthermore, whether GK treatment should be considered for intractable epilepsy arising in other functional cortical regions that can not be treated with resection remains unexplored.

In a review on the application of SRS to disorders of the brain, Kondziolka et al (2008) noted that radiosurgery has had an impact on the management of patients with vascular malformations, all forms of cerebral neoplasia, and selected functional disorders such as trigeminal neuralgia and tremor. Epilepsy, behavioral disorders, and other novel indications are the topics of current investigation. This is in agreement with the observation of Quigg and Barbaro (2008) who stated that further studies are needed to ascertain if the effectiveness of SRS for treatment of epilepsy attains that of traditional surgery while offering a non-invasive technique with potentially lower morbidity.

Stereotactic radiosurgery is being investigated as a treatment for cluster headache. In a prospective open trial, Donnet, et al. (2005) examined the effectiveness of gamma knife radiosurgery of the trigeminal nerve in the treatment of patients with chronic cluster headache (CCH).  A total of 10 patients (9 men, 1 woman; mean age of 49.8 years) were enrolled.  They presented with severe and drug resistant CCH (mean duration of 9 years).  The cisternal segment of the trigeminal nerve was targeted with a single 4-mm collimator (80 to 85 Gy max).  The mean follow-up was 13.2 months.  No improvement was observed in 2 patients, while 3 patients had no further attacks.  Three patients showed dramatic improvement with a few attacks per month or very few attacks over the last 6 months.  Two patients were pain-free for only 1 week and 2 weeks, respectively, and their headaches recurred with the same severity as before.  Three patients developed paresthesia with no hypoesthesia, 1 developed hypoesthesia, and 1 developed de-afferentation pain.  These investigators considered the morbidity to be significant for the low rate of pain cessation, making this procedure less attractive even for the more severely affected subgroup of patients.